Current stage-Stage I-I-B Posts on Medivizor
Navigation Menu

Current stage-Stage I-I-B Posts on Medivizor

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Posted by on Mar 26, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC. Some background Non-small cell lung cancer (NSCLC)...

Read More

Does Oncotype DX testing reduce the use of chemotherapy in patients with estrogen receptor positive breast cancer?

Does Oncotype DX testing reduce the use of chemotherapy in patients with estrogen receptor positive breast cancer?

Posted by on Jul 9, 2013 in Breast cancer | 0 comments

In a nutshell In this study, researchers evaluated whether a genetic test called Oncotype DX, reduced the use of chemotherapy treatment for patients with node-positive and estrogen-receptor positive breast cancer. Some background Some breast cancers grow in response to estrogen, the main female sex hormone, via their receptor (a protein found on...

Read More

Risk of Heart Failure after Anthracycline (Adriamycin/Daunomycin) and Trastuzumab (Herceptin) Treatments for Breast Cancer

Risk of Heart Failure after Anthracycline (Adriamycin/Daunomycin) and Trastuzumab (Herceptin) Treatments for Breast Cancer

Posted by on Mar 19, 2013 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk of heart disease associated with two commonly prescribed treatments for breast cancer. The main finding was that Trastuzumab (Herceptin) and Anthracycline (Adriamycin/Daunomycin) treatments are associated with a higher risk of heart failure or ‘cardiomyopathy’. Some background Anthracyclines...

Read More